Athersys Stock News

Fly Intel: Pre-market Movers ATHX TDOC TSLA ALK AAL DAL HA JBLU UAL SKYW LUV UNH CACI BAC C GS USB ASML DVN CCMP

The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs April 14) Bio-Rad Laboratories, Inc...

Fly Intel: After-Hours Movers BBBY RCUS GILD AXDX VNDA JACK NDLS AWK COST ATHX CALA AFG ARCT PFGC CLDR HEI GPRO

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares climbed 61.7% to close at $7.99 on Tuesday. NeuroMetrix, Inc. (NASDAQ: NURO) shares gained 58.7% to close at $...

The Global Tissue Engineering Market is expected to grow from USD 19,423.13 Million in 2018 to USD 61,236.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 17.82%. Read the full

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares jumped 179% to $13.77. NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 47.6% to $2.79 after surging over 42% on...

When Athersys pivoted to Covid-19, its market value jumped to nearly $600 million. That's unjustified, given questions about its stem cell treatment.

Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Needham analyst Chad Messer maintained a Buy rating on Athersys (ATHX) today and set a price target of $6.00. The company's shares closed last Monday at